<DOC>
	<DOCNO>NCT00004256</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Drugs sargramostim may protect normal cell side effect radiation therapy . PURPOSE : Randomized phase II trial determine effectiveness sargramostim prevent mucositis patient receive radiation therapy laryngeal cancer .</brief_summary>
	<brief_title>Sargramostim Prevent Mucositis Patients Receiving Radiation Therapy Laryngeal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine efficacy sargramostim ( GM-CSF ) reduce duration severity mucositis result accelerated radiotherapy patient laryngeal carcinoma . - Determine effect GM-CSF quality life aspects patient assess nutritional status , analgesic use , day hospital . OUTLINE : This randomize study . Patients receive radiotherapy 16 fraction 21 day . Patients randomly allocate one two treatment arm schedule radiotherapy begin . - Arm I : Patients receive sargramostim ( GM-CSF ) SC daily 14 day begin day 14 course radiotherapy . - Arm II : Patients receive GM-CSF . Patients follow weekly mucositis heal , well week 2 6 follow end radiotherapy . PROJECTED ACCRUAL : A total 34 patient ( 17 per arm ) accrue study .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Radiation Injuries</mesh_term>
	<mesh_term>Laryngeal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis laryngeal cancer intention treat radiotherapy use 16 fraction 3 week scheme Stage I II No know CNS disease PATIENT CHARACTERISTICS : Age : 20 80 Performance status : WHO 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Hepatic function normal Renal : Renal function normal Other : Not pregnant nursing No serious active infection require antibiotic therapy No autoimmune disease No known seizures No psychosocial factor would preclude study compliance No allergy sargramostim ( GMCSF ) Willingness cooperate regular mirror examination larynx PRIOR CONCURRENT THERAPY : Biologic therapy : No concurrent immunotherapy Chemotherapy : No concurrent chemotherapy Endocrine therapy : No prior concurrent corticosteroid No concurrent hormonal therapy Radiotherapy : See Disease Characteristics Surgery : No major organ allograft Other : No concurrent investigational drug</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2006</verification_date>
	<keyword>stage I laryngeal cancer</keyword>
	<keyword>stage II laryngeal cancer</keyword>
	<keyword>recurrent laryngeal cancer</keyword>
	<keyword>oral complication</keyword>
	<keyword>radiation toxicity</keyword>
</DOC>